# of Displayed Technologies: 10 / 70

Applied Category Filter (Click To Remove): Life & Health Sciences


Categories

FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
  • College: College of Medicine (COM)
  • Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
  • Licensing Officer: Csatary, Erika

Diagnostic for Early Detection of Heart Damage
TS-059578 — A novel biomarker for the early identification of cardiac damage, including chemotherapy-induced cardiotoxicity.
Despite significant medical advances and technologies, cardiovascular disease remains the number one cause of death in the United States, irrespective of gender or race, resulting in more than 600,000 annual deaths. Additionally, while cancer survivorship has increased significantly, the number one …
  • College: College of Medicine (COM)
  • Inventors: Smith, Sakima; Dib, Patrick; McElroy, Craig
  • Licensing Officer: Csatary, Erika

Metabolite-Based Diagnostics for Joint Infection
TS-059537 — An untargeted NMR-based metabolomics approach to identify metabolic compounds as signatures of bacterial joint infections and methods for the treatment and prevention thereof.
Pseudomonas aeruginosa, a biofilm-producing pathogenic bacterium, exhibits resistance to many antibiotics. This leads to acute and chronic joint infections that are difficult to treat. Accordingly, a critical need exists for accurate biofilm diagnosis, prevention, and treatment. While culture-free…
  • College: College of Medicine (COM)
  • Inventors: Stoodley, Paul; Bruschweiler, Rafael; Leggett, Abigail
  • Licensing Officer: Csatary, Erika

Temperature-sensitive SARS-CoV-2 mutant TS11 for vaccine development
TS-059103 — Novel temperature-sensitive SARS-CoV-2 mutant
Current COVID-19 vaccines (mRNA, adenovirus vector, inactivated, S protein) are effective in preventing severe COVID-19 cases and deaths. However, they do not prevent infection/virus transmission and as the virus continues to evolve, S mutants may emerge that can escape current vaccine-induced immun…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Wang, Qiuhong; Liu, Mingde; Niu, Xiaoyu; Saif, Linda; Xu, Jiayu
  • Licensing Officer: Dahlman, Jason "Jay"

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

X-Ray Assistive Device for Standardizing the Knee Templating Process
TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.
Over 600,000 knee replacements are performed per year. As part of the pre-operative planning for surgery, x-ray images are taken to determine the proper fit for the implant. Even with the use of a calibration ball, this knee templating procedure remains inaccurate and unreliable for a number of re…
  • College: College of Engineering (COE)
  • Inventors: Ruegsegger, Mark; Aery, Dylan; Browske, Kimberly; Cantrell, Kaleb "Kaleb"; Reilman, Zach; Thew, Maddie
  • Licensing Officer: Randhawa, Davinder

Therapeutic uses of the scavenging protein cocktail to treat plasma protein imbalances or depletion
TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.
Fluid replacement as part of resuscitation efforts in clinical care is a cornerstone of treatment especially in cases with severe trauma. The regular usage of these fluids in hospitals requires the mixture to be easily transported, easily stored and applicable across a wide variety of patients. To…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Schworer, Adam

Show More Technologies

Loading icon